Chemours Co (NYSE:CC) VP Mark Newman sold 29,381 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $49.19, for a total value of $1,445,251.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Chemours Co (CC) traded up $1.47 on Friday, reaching $50.06. The company’s stock had a trading volume of 1,237,896 shares, compared to its average volume of 1,970,000. The company has a debt-to-equity ratio of 4.74, a quick ratio of 1.55 and a current ratio of 2.12. The stock has a market capitalization of $9,140.00 and a P/E ratio of 9.57. Chemours Co has a one year low of $32.31 and a one year high of $58.08.
Chemours (NYSE:CC) last posted its earnings results on Wednesday, February 14th. The specialty chemicals company reported $1.19 EPS for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.24. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.55 billion. Chemours had a return on equity of 115.54% and a net margin of 12.06%. Chemours’s quarterly revenue was up 19.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.08 earnings per share. equities analysts anticipate that Chemours Co will post 5.3 EPS for the current fiscal year.
A number of research analysts recently weighed in on the company. Barclays reaffirmed a “buy” rating and set a $60.00 price objective on shares of Chemours in a report on Wednesday, December 6th. Morgan Stanley assumed coverage on Chemours in a report on Tuesday, January 30th. They set an “equal weight” rating and a $57.50 price objective on the stock. Zacks Investment Research raised Chemours from a “hold” rating to a “strong-buy” rating and set a $58.00 price objective on the stock in a report on Wednesday, February 21st. Goldman Sachs Group lowered Chemours from a “buy” rating to a “neutral” rating and set a $55.00 price objective on the stock. in a report on Wednesday, December 6th. Finally, Jefferies Group upped their price objective on Chemours to $66.00 and gave the stock a “buy” rating in a report on Monday, December 4th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $57.95.
Institutional investors and hedge funds have recently bought and sold shares of the business. Strs Ohio purchased a new stake in Chemours during the fourth quarter worth $116,000. Clearbridge LLC boosted its position in Chemours by 93.6% during the fourth quarter. Clearbridge LLC now owns 2,689 shares of the specialty chemicals company’s stock worth $135,000 after purchasing an additional 1,300 shares in the last quarter. First Allied Advisory Services Inc. purchased a new stake in Chemours during the third quarter worth $202,000. Gamco Investors INC. ET AL purchased a new stake in Chemours during the third quarter worth $202,000. Finally, Bell Bank purchased a new stake in Chemours during the third quarter worth $202,000. Institutional investors own 76.92% of the company’s stock.
Chemours Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.